# Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

> **NCT07042919** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwestern University** · enrollment: 53 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Cirrhosis
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07042919
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2029-03-04
- **Final completion:** 2031-03-04
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07042919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07042919, "Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07042919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*